Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2016
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 Nov 2016 Status changed from active, no longer recruiting to completed.
- 21 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 11 Jun 2013 Planned end date changed from 1 Dec 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.